US Product Portfolio for Orthopedic Biomaterials 2017 - MedFolio

Publisher Name :
Date: 01-Mar-2017
No. of pages: 502
Inquire Before Buying

General Report Contents

- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends

- Market Drivers & Limiters for each chapter segment

- Competitive Analysis for each chapter segment

- Section on recent mergers & acquisitions

Orthopedic biomaterials are associated with high research and development (R&D) costs, which have subsequently led to premium pricing to recoup these initial costs. This is the case for competitors in the cellular allograft, cell therapy and growth factor segments of the U.S. orthopedic biomaterials market. In particular, orthopedic growth factors have had relatively high average selling prices (ASP) since their introduction to the market due to the high costs of recombinant growth factor technologies. The high R&D costs associated with the growth factor segment provide entry barriers against potential competitors. Currently there are only two growth factor BMP-2 products in the United States. Since they're both used in different indications, there is a lack of direct competition, allowing companies such as Medtronic to charge a premium for the Spine indication and recover the large initial costs associated with R&D. The commoditized nature in some parts of the market, such as the allograft and DBM segments, which is due to the lack of product differentiation, has limited growth. The market is being driven by more competitors venturing outside their traditional space to tap into the high growth segments where they can charge a premium. These segments may include the cell therapy and cellular allograft segments, both of which have relatively high ASP.

The full report suite on the U.S. market for orthopedic biomaterials includes bone graft substitutes, which is represented by allografts, demineralized bone matrix, and synthetic bone graft market. The report also includes orthopedic growth factors, cellular allografts, orthopedic cell therapy, hyaluronic acid viscosupplementation, orthopedic cartilage repair, and spinal machined bone allograft markets.

Scope

2013-2023

Companies

Medtronic
Genzyme
DePuy Synthes
Anika Therapeutics
Ferring Pharmaceuticals
Stryker
NuVasive
Bioventus
Zimmer Biomet
Integra LifeSciences
RTI Surgical
Fidia Pharmaceuticals
MTF
Orthofix
Arthrex
AlloSource
Aastrom
Baxter
Harvest Technologies
Wright Medical
Bacterin International
Arteriocyte
Exactech
LifeNet Health
Biocomposites
Alphatec Spine
Celling Biosciences
Globus Medical
Nuo Therapeutics
K2M
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.

US Product Portfolio for Orthopedic Biomaterials 2017 - MedFolio

Table Of Contents I
List Of Figures XVIII
List Of Charts XXIII
Executive Summary 1
U.S. Orthopedic Biomaterials Market Overview 1
Competitive Analysis 4
Market Trends 6
Market Developments 8
Procedure Numbers 9
Markets Included 11
Key Report Updates 13
Version History 13
Research Methodology 14
1.1 Research Scope 14
1.2 Idata's 9-Step Methodology 14
Step 1: Project Initiation & Team Selection 14
Step 2: Prepare Data Systems And Perform Secondary Research 16
Step 3: Preparation For Interviews & Questionnaire Design 17
Step 4: Performing Primary Research 18
Step 5: Research Analysis: Establishing Baseline Estimates 20
Step 6: Market Forecast And Analysis 21
Step 7: Identify Strategic Opportunities 23
Step 8: Final Review And Market Release 24
Step 9: Customer Feedback And Market Monitoring 25
Disease Overview 26
2.1 Basic Anatomy 26
2.1.1 Osteology And Musculoskeletal System 26
2.2 Disease Pathology And Disorders 28
2.2.1 General Diagnostic 28
2.2.2 Osteoporosis 29
2.2.3 Osteoarthritis 29
2.2.4 Indication For Bone Graft Procedure 30
2.2.5 Indication For Cartilage Repair 31
2.2.6 Degenerative Disc Disease 32
2.3 Patient Demographics 34
2.3.1 General Statistics 34
Product Assessment 36
3.1 Product Portfolios 36
3.1.1 Bone Graft Substitutes 37
3.1.2 Growth Factors 41
3.1.2.1 Other Products 44
3.1.3 Cellular Allografts 46
3.1.4 Cell Therapy 50
3.1.5 Hyaluronic Acid Viscosupplementation 54
3.1.6 Cartilage Repair 57
3.1.7 Spinal Machined Bone Allografts 59
3.2 Regulatory Issues And Recalls 62
3.2.1 Bone Graft Substitutes 62
3.2.2 Growth Factors 65
3.2.3 Cell Therapy 66
3.2.4 Hyaluronic Acid Viscosupplementation 67
3.2.5 Cartilage Repair 68
3.2.6 Spinal Machined Bone Allografts 69
3.3 Clinical Trials 70
3.3.1 Bone Graft Substitutes 70
3.3.2 Growth Factors 75
3.3.3 Cellular Allografts 80
3.3.4 Cell Therapies 86
3.3.5 Hyaluronic Acid Viscosupplementation 88
3.3.6 Cartilage Repair 92
3.3.7 Spinal Machined Bone Allografts 97
Abbreviations 103
Appendix Ii: Company Press Releases 105

List Of Figures

Figure 1 1: Orthopedic Biomaterials Market Share Ranking By Segment, U.S., 2016 (1 Of 2) 4
Figure 1 2: Orthopedic Biomaterials Market Share Ranking By Segment, U.S., 2016 (2 Of 2) 4
Figure 1 3: Companies Researched In This Report, U.S., 2016 5
Figure 1 4: Factors Impacting The Orthopedic Biomaterials Market By Segment, U.S. (1 Of 2) 6
Figure 1 5: Factors Impacting The Orthopedic Biomaterials Market By Segment, U.S. (2 Of 2) 7
Figure 1 6: Recent Events In The Orthopedic Biomaterials Market, U.S., 2013 - 2016 8
Figure 1 7: Orthopedic Biomaterials Markets Covered, U.S., 2016 (1 Of 2) 9
Figure 1 8: Orthopedic Biomaterials Markets Covered, U.S., 2016 (2 Of 2) 10
Figure 1 9: Orthopedic Biomaterials Markets Covered, U.S., 2016(1 Of 3) 11
Figure 3 1: Bone Graft Substitutes Products By Company (1 Of 3) 38
Figure 3 2: Bone Graft Substitutes Products By Company (2 Of 3) 39
Figure 3 3: Bone Graft Substitutes Products By Company (3 Of 3) 40
Figure 3 4: Growth Factors Products By Company 45
Figure 3 5: Estimates Of Funding For Stem Cell Research 48
Figure 3 6: Cellular Allograft Products By Company 49
Figure 3 7: Cell Therapy Products By Company 53
Figure 3 8: Hyaluronic Acid Viscosupplementationby Products By Company 56
Figure 3 9: Cartilage Repair Products By Company 58
Figure 3 10: Spinal Machined Bone Allograft Products By Company 61
Figure 3 11: Class 2 Device Recall Endobon Xenograft Granules 62
Figure 3 12: Class 2 Device Recall Accell Evo3c Demineralized Bone Matrix Putty 62
Figure 3 13: Class 2 Device Recall Allofuse Dbm Putty 5cc 62
Figure 3 14: Class 2 Device Recall Microfuse Bone Void Filler 63
Figure 3 15: Class 2 Device Recall Grafton 63
Figure 3 16: Class 2 Device Recall Optimum Expanse 63
Figure 3 17: Class 2 Device Recall Integra Mozaik 64
Figure 3 18: Class 2 Device Recall Infuse(R) Bone Graft 65
Figure 3 19: Class 2 Device Recall Stryker Biotech 65
Figure 3 20: Class 2 Device Recall Oncontrol 66
Figure 3 21: Class 2 Device Recall Graft Delivery System 66
Figure 3 22: Class 3 Device Recall EufleXXa (1 Sodium Hyaluronate) 67
Figure 3 23: Class 2 Device Recall Smith & Nephew 68
Figure 3 24: Class 2 Device Recall Surgical Saw Blade Procedure Pack 68
Figure 3 25: Class 2 Device Recall Stryker Radius Spinal System 69
Figure 3 26: An Acdf Multi-Center Study Using Vivigen Cellular Bone Matrix 70
Figure 3 27: Cerament Treatment Of Fracture Defects (Certify) 70
Figure 3 28: Synthetic Bone Graft Substitute Vs. Autologous Spongiosa In Revision Anterior Cruciate Ligament Reconstruction 71
Figure 3 29: Assessment Of Nanoss Bioactive 3d In The Posterolateral Spine 71
Figure 3 30: Attrax® Putty Vs. Autograft In Xlif® 71
Figure 3 31: Evaluation Of Fusion Rate Using K2m Vesuvius® Demineralized Fibers With K2m Everest® Spinal System 72
Figure 3 32: Clinical Evaluation Of Genex® Ds In Instrumented Posterolateral Fusion 72
Figure 3 33: Efficacy And Safety Of Surgifill™ On Spinal Fusion 72
Figure 3 34: Evaluation Of Dtrax Graft In Patients With Cervical Degenerative Disc Disease 73
Figure 3 35: Comparison Of Nanoss Bioactive With Autograft And Bone Marrow Aspirate To Autograft In The Posterolateral Spine 73
Figure 3 36: Evaluation Of Fusion Rate Of Anterior Cervical Discectomy And Fusion (Acdf) Using Cervios Chronos™ And Bonion™ 74
Figure 3 37: A Study Of Infuse Bone Graft (Bmp-2) In The Treatment Of Tibial Pseudarthrosis In Neurofibromatosis Type 1 75
Figure 3 38: A Prospective Study Of Instrumented, Posterolateral Lumbar Fusions (Plf) With Osteoamp® 75
Figure 3 39: The Clinical Effect Of I-Factor® Versus Allograft In Non-Instrumented Posterolateral Spondylodesis Operation 76
Figure 3 40: Clinical Study Of Infuse® Bone Graft Compared To Autogenous Bone Graft For Vertical Ridge Augmentation 76
Figure 3 41: Rct Of Attrax® Putty Vs. Autograft In Instrumented Posterolateral Spinal Fusion (Axa) 77
Figure 3 42: Clinical Study Of Injectable Ceramics Bone Graft Substitute Containing Rhbmp-2 77
Figure 3 43: Prospective Study Of Safety And Efficacy Of Inqu® Bone Graft Extender In Lumbar Interbody Fusion Surgery (Intebody) 78
Figure 3 44: Long-Term Safety And Effectiveness Of Augment® Bone Graft Compared To Autologous Bone Graft 78
Figure 3 45: Rhbmp-2 Vs Autologous Bone Grafting For The Treatment Of Non-Union Of The Docking Site In Tibial Bone Transport 79
Figure 3 46: Evaluation Of Radiculitis Following Use Of Bone Morphogenetic Protein-2 For Interbody Arthrodesis In Spinal Surgery 79
Figure 3 47: Transplantation Of Autologous Bone Marrow Or Leukapheresis-Derived Stem Cells For Treatment Of Spinal Cord Injury 80
Figure 3 48: Safety And Efficacy Of Autologous Mesenchymal Stem Cells In Chronic Spinal Cord Injury 80
Figure 3 49: Rhbmp-2 In Cervical Arthrodesis 81
Figure 3 50: Interbody Spacers With Map3® Cellular Allogeneic Bone Graft In Anterior Or Lateral Lumbar Interbody Fusion 81
Figure 3 51: Bmac & Allograft Vs Bmp-2 82
Figure 3 52: Human Autograft Mesenchymal Stem Cell Mediated Stabilization Of The Degenerative Lumbar Spine 82
Figure 3 53: Regenerative Medicine Of Articular Cartilage: Characterization And Comparison Of Chondrogenic Potential And Immunomodulatory Adult Mesenchymal Stem Cells (Arthrostem) 83
Figure 3 54: Autologous Mesenchymal Stem Cells Transplantation For Spinal Cord Injury- A Phase I Clinical Study 83
Figure 3 55: Mesenchymal Stem Cells In Knee Cartilage Injuries 84
Figure 3 56: A Clinical Study Of Outcomes In Foot And Ankle Bone Grafting Using Map3® Cellular Allogeneic Bone Graft 84
Figure 3 57: Treatment Of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (Msv_Allo) 85
Figure 3 58: Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation (Bm-Msc) For Kienbock's Disease 86
Figure 3 59: The Effect Of Platelet Rich Plasma (Prp) On Post Operative Pain In Anterior Cruciate Ligament Reconstruction 86
Figure 3 60: Comparative Assessment Of Intra-Articular Knee Injections Of Platelet-Rich Plasma (Prp) And Hyaluronic Acid 87
Figure 3 61: Evaluation Of Safety And Exploratory Efficacy Of Cartistem®, A Cell Therapy Product For Articular Cartilage Defects 87
Figure 3 62: Trial Comparing Botulin ToXIn Versus Hyaluronic Acid By Intra-Articular Injection (Gotox) 88
Figure 3 63: Trial To Assess The Structural Effect And Long-Term Symptomatic Relief Of Intra-Articular Injections Of Ha (Viscoa) 88
Figure 3 64: Platelet-Rich Plasma Vs. Hyaluronic Acid For Glenohumeral Osteoarthritis 89
Figure 3 65: Comparative Assessment Of Viscosupplementation With Polynucleotides And Hyaluronic Acid (Pnha1401) 89
Figure 3 66: To Look At The Characteristics Of Synovial Fluid And Cartilage Matrix In Osteoarthritic Knee After Hyaluronic Acid Injection 90
Figure 3 67: Platelet-Rich Plasma Vs Viscosupplementation In The Treatment Of Knee Articular Degenerative Pathology (Prp) 90
Figure 3 68: Platelet-Rich Plasma Intra-Articular Injection In Treating Hemophilic Arthropathy 91
Figure 3 69: Effectiveness Of Two Hyaluronic Acids In Osteoarthritis Of The Knee 91
Figure 3 70: Denovo Nt Longitudinal Data Collection (Ldc) Knee Study 92
Figure 3 71: Novocart®3d For Treatment Of Articular Cartilage Of The Knee (N3d) 92
Figure 3 72: Porous Tissue Regenerative Silk Scaffold For Human Meniscal Cartilage Repair (Rekreate) 93
Figure 3 73: Confirmatory Study Of Neocart In Knee Cartilage Repair 93
Figure 3 74: The Efficacy And Safety Of A Modified Microfracture Using Collagen Compared To Those Of A Simple Microfracture In Ankle 94
Figure 3 75: Efficacy Of Bst-Cargel In Treating Chondral Lesions Of The Hip 94
Figure 3 76: Biphasic Cartilage Repair Implant (Bicri) Ide Clinical Trial - Taiwan 95
Figure 3 77: A Study To Compare Two Techniques For Articular Cartilage Repair:Acic Vs. Mcic 95
Figure 3 78: Second Line Treatment Of Knee Osteochondral Lesion With Treated Osteochondral Graft (Odphoenix2) 96
Figure 3 79: Neocartilage Implant To Treat Cartilage Lesions Of The Knee 96
Figure 3 80: Study Of Nucel For One And Two Level Lumbar Interbody Fusion 97
Figure 3 81: An Acdf Multi-Center Study Using Vivigen Cellular Bone Matrix 97
Figure 3 82: An Assessment Of P-15 Bone Putty In Anterior Cervical Fusion With Instrumentation 98
Figure 3 83: Interbody Spacers With Map3® Cellular Allogeneic Bone Graft In Anterior Or Lateral Lumbar Interbody Fusion 98
Figure 3 84: Efficacy Study Of Nucel® In Patients Undergoing Fusion Of The Lumbar Spine 99
Figure 3 85: Prospective Study Of Thoracolumbar Spinal Fusion Graft (Bmac) 99
Figure 3 86: Cellentra Viable Cell Bone Matrix (Vcbm) Anterior Cervical Discectomy And Fusion Outcomes Study (Vcbm/Maxan) (Vcbm/Acdf) 100
Figure 3 87: Prospective Study Of Thoracolumbar Spinal Fusion Graft (Bmac) 100
Figure 3 88: Peek And Allograft Spacers Evaluation In Spinal Fusion Surgeries (Peek) 101
Figure 3 89: Restore Clinical Trial 101
Figure 3 90: A Prospective Study Of Nucel® In Cervical Spine Fusion 102
Figure 3 91: Safety And Preliminary Efficacy Study Of Neofuse In Subjects Undergoing Multi-Level Anterior Cervical Discectomy 102
Figure 5 1: Press Release Summary 105

List Of Charts

Chart 1 1: Orthopedic Biomaterials Market By Segment, U.S., 2013 - 2023 3
Chart 1 2: Orthopedic Biomaterials Market Overview, U.S., 2016 & 2023 3

  • 2017-2022 Japan Cervical Interbody Fusion Cages Market Report (Status and Outlook)
    Published: 20-Jul-2017        Price: US 3360 Onwards        Pages: 111
    "This report will be delivered in 2-3 business days after the order is placed." The Cervical Interbody Fusion Cages market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include Medtronic Depuy Synthes Stryker Zimmer Biomet BBraun N......
  • 2017-2022 Malaysia Cervical Interbody Fusion Cages Market Report (Status and Outlook)
    Published: 20-Jul-2017        Price: US 3360 Onwards        Pages: 111
    "This report will be delivered in 2-3 business days after the order is placed." The Cervical Interbody Fusion Cages market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Malaysia market, the top players include Medtronic Depuy Synthes Stryker Zimmer Biomet BBraun ......
  • 2017-2022 Philippines Cervical Interbody Fusion Cages Market Report (Status and Outlook)
    Published: 20-Jul-2017        Price: US 3360 Onwards        Pages: 111
    "This report will be delivered in 2-3 business days after the order is placed." The Cervical Interbody Fusion Cages market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Philippines market, the top players include Medtronic Depuy Synthes Stryker Zimmer Biomet BBraun......
  • 2017-2022 United States Cervical Interbody Fusion Cages Market Report (Status and Outlook)
    Published: 20-Jul-2017        Price: US 3360 Onwards        Pages: 111
    "This report will be delivered in 2-3 business days after the order is placed." The Cervical Interbody Fusion Cages market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In United States market, the top players include Medtronic Depuy Synthes Stryker Zimmer Biomet BBr......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Hydroxyapatite-coated Femoral Components Market 2017 Forecast to 2022
    Published: 20-Jul-2017        Price: US 4880 Onwards        Pages: 124
    Hydroxyapatite-coated Femoral Components refers to a hard tissue implant material coated with hydroxyapatite on femur components using titanium as a base and physically and chemically. After the material is implanted into the human body, the titanium alloy can provide sufficient mechanical strength, the surface of the hydroxyapatite coating is easy to combine with the human bone, in the human bone surface induced new bone formation, generally months to induce new bone formation.Scope ......
  • United States External Fixator Market Report 2017
    Published: 20-Jul-2017        Price: US 3800 Onwards        Pages: 114
    In this report, the United States External Fixator market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of......
  • 2017 Top 5 Cervical Interbody Fusion Cages Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 20-Jul-2017        Price: US 4960 Onwards        Pages: 159
    "This report will be delivered in 2-3 business days after the order is placed." The Global Cervical Interbody Fusion Cages market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Cervical Interbody Fusion Cages in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Cer......
  • 2017-2022 China Cervical Interbody Fusion Cages Market Report (Status and Outlook)
    Published: 20-Jul-2017        Price: US 3360 Onwards        Pages: 111
    "This report will be delivered in 2-3 business days after the order is placed." The Cervical Interbody Fusion Cages market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include Medtronic Depuy Synthes Stryker Zimmer Biomet BBraun N......
  • 2017-2022 Global Top Countries Cervical Interbody Fusion Cages Market Report
    Published: 20-Jul-2017        Price: US 4960 Onwards        Pages: 159
    "This report will be delivered in 2-3 business days after the order is placed." The Global Cervical Interbody Fusion Cages market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Cervical Interbody Fusion Cages in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, South......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs